Led · Equity · Nov 2025

Kraken operates a cryptocurrency exchange and is run by parent company Payward Inc. The company has pursued strategic partnerships with traditional financial infrastructure players, most recently teaming with Deutsche Börse to enhance access for institutional clients across trading, custody, settlement, collateral management, and tokenized assets. In November, Kraken announced an $800 million fundraising that included a $200 million investment from Citadel Securities. Plans for an initial public offering were announced last year but have been deferred amid unfavorable market conditions. The Deutsche Börse investment values Kraken at roughly $13.3 billion and is expected to close pending regulatory approval. Beyond trading, the partnership with Deutsche Börse and other initiatives aim to expand Kraken's institutional product set in Europe.

Led · Equity · Nov 2025

Swarmer builds artificial-intelligence software that enables coordinated operation of multiple drones, creating autonomous swarms for defense purposes. The company’s technology is positioned for military and dual-use applications, and it has become one of the best-funded players in Ukraine’s MilTech sector. Following Russia’s full-scale invasion, Swarmer attracted significant local and international attention and previously secured a record $15 million for Ukrainian defense technology. Its latest capital will support continued product development and scaling of its swarm-control platform. The firm works within Ukraine’s growing defense-tech ecosystem and collaborates with initiatives such as Brave1 and Sikorsky Challenge through its new investor network. Financial details beyond the disclosed fund-raises (revenue, user counts, or deployment figures) were not provided in the article.

Led · Series C · Mar 2023

Perspectum develops software that enhances standard MRI machines to capture multiparametric mapping data and uses AI to measure organ inflammation and aid diagnosis and monitoring. Its flagship product, LiverMultiScan, has had coverage for roughly 77 million U.S. adults since early 2021 and has been adopted by several major U.S. hospitals. The company also offers FDA-approved MRCP+ technology and is building a platform-based product portfolio for clinical research and clinical use. Perspectum plans to expand its footprint across the U.S. and scale operations to meet growing demand for organ-health assessment. The new funding will be used to scale U.S. operations and accelerate the product pipeline for multiorgan conditions and oncology. Perspectum maintains offices in the U.S., the U.K., Portugal, and Singapore. Perspectum builds software that augments standard MRI machines to capture multiparametric mapping data and uses AI to measure organ inflammation, offering non-invasive alternatives to biopsy. Its flagship product, LiverMultiScan, assesses and monitors chronic liver disease. Since the beginning of 2021, 77 million US adults covered by Medicare and commercial plans have had access to LiverMultiScan. The company has established reimbursement codes and adoption by several major US hospitals and announced a collaboration with Nuance (a Microsoft company) in December 2022. Perspectum plans to scale its US operations, grow its customer base, and accelerate its product pipeline for multiorgan inflammatory conditions and oncology using the new funding. The company has offices in the US, the UK, Portugal, and Singapore. Perspectum develops non-invasive medical imaging software, including LiverMultiScan, which extracts quantitative data from routine MRI scans to aid detection and monitoring of chronic liver disease. LiverMultiScan is FDA-cleared and described in the article as having proven accuracy and precision in assessing liver tissue. The company also operates an imaging-focused CRO that supports biopharmaceutical companies developing assets in liver and metabolic diseases. The $36M financing announced will be used to commercialize LiverMultiScan for clinical use, expand the CRO business, and develop additional products targeting biliary disease, diabetes and cancer for both clinical and CRO applications. Perspectum is actively evaluating its technology in China and is positioned to support drug development and clinical deployment as new NASH therapies approach approval. The company emphasizes precision medicine using advanced imaging and genetics to enable early detection, diagnosis, and targeted treatment.

Participated · Series A · Aug 2022

All G Foods is developing high-value milk proteins through a proprietary precision-fermentation platform, allowing it to create bovine and human lactoferrin with high purity (>95%) and scalable yields. The company has completed pilot-scale production of recombinant bovine lactoferrin, has self-affirmed GRAS status for adult nutrition in the U.S., and secured approval for personal-care use in China. Its first commercial product, a bovine lactoferrin powder, is planned for launch in late 2025, followed by human lactoferrin in early 2026. To accelerate scale-up and commercialization, All G formed a joint venture with French dairy-bioactives leader Armor Protéines, leveraging Armor’s manufacturing expertise and global distribution relationships. All G has filed multiple patents covering micelle assembly, scalable manufacture and human milk compositions. The company’s technology aims to lower costs, improve supply stability and broaden access to lactoferrin, which traditionally requires thousands of litres of cow’s milk per kilogram produced. Headquartered in Waterloo, New South Wales, the firm positions itself at the intersection of early-life nutrition, adult health supplements and precision-fermented bioactives.

Participated · Equity · Nov 2018

Valens develops HDBaseT technology for the audiovisual and automotive markets. Its HDBaseT Automotive chip technology enables in-vehicle connectivity by converging audio and video, Ethernet, USB, controls, PCIe, and power over a single cable. HDBaseT is used by audio/video component manufacturers. Led by CEO and co-founder Dror Jerushalmi, Valens is advancing audio/visual chipset technology into the automotive world. The company raised $63M to accelerate development of its portfolio for the autonomous vehicle sector and to address the ongoing requirements of its automotive partners. Valens is based in Hod HaSharon, Israel. Valens develops semiconductor products for the distribution of ultra‑high‑definition multimedia content, with a focus on long‑reach connectivity over a single cable. Its HDBaseT automotive technology, introduced in 2016, targets connected‑car challenges by enabling infotainment and ADAS bandwidth and wiring needs. The company was established in 2006 by Dror Jerushalmi and is based in Hod Hasharon, Israel. Valens recently secured additional equity financing to accelerate product development and time to market. Management says the funds will be used to develop additional products to meet market demand and to support customers with design and development projects. As part of the financing, a new investor representative will join the board. Valens Semiconductor is a fabless company that supplies semiconductor products for distributing uncompressed high-definition multimedia and invented the HDBaseT technology. Its HDBaseT technology enables long-reach connectivity of devices over a single 100m/328ft standard CAT5e/6 LAN cable. The company develops HDBaseT chipsets and says it will use the funding to accelerate development of follow-on generations of its chipset, enabling further integration and cost reduction. Valens expects these improvements to facilitate growth in multimedia transmission and data communication for consumer electronics. Founded in 2006 and privately held, Valens has offices in Israel, Japan, Hong Kong, and the USA, with local representatives in Korea, Taiwan, and China. The recent financing provides additional capital to support product development and market expansion.